Results for all evidence | Scottish Medicines Consortium - SMC 51 - 60 of 3317 sorted by relevance / date

Indication: as testosterone replacement therapy in men with primary or secondary hypogonadism.

Indication: for the treatment of testosterone replacement therapy

Indication: Add-on therapy for children (6y+), adolescents, and adults with severe refractory eosinophilic asthma

Indication: Elevated intra-ocular pressure in patients with open-angle glaucoma and pseudo-exfoliative glaucoma

Indication: As monotherapy, for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.

Indication: For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

Indication: treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

Indication: monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are...

Indication: As monotherapy for the treatment of locally advanced or metastatic or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy (first line)

Indication: As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.